• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Abuse-deterrent opioids are costly and unproven

August 10, 2017 By Sarah Faulkner

Prescription drugsIn an attempt to curb the harrowing opioid crisis in America, drugmakers have developed what they tout as “abuse-deterrent” pain-killers – opioid formulations that are designed to prevent users from injecting the drugs.

But a report published this week by the Institute of Clinical and Economic Review found that there isn’t enough evidence to claim that these re-formulated drugs effectively reduce abuse and that the price of abuse-deterrent opioids is a barrier for large-scale adoption.

The report pointed out that while many manufacturers try to produce opioids that are tougher to inject or crush compared to traditional pain-killers, the most common route of opioid abuse is simply swallowing more pills.

The institute added that there is some data suggesting that abuse-deterrent opioids can inadvertently push people who are trying to abuse the drug to more dangerous substances, like heroin.

Earlier this year, the FDA asked Endo Pharmaceuticals (NSDQ:ENDP) to withdraw its abuse-deterrent opioid, Opana ER, from the market. The agency argued that the benefits of the abuse-deterrent drug no longer outweigh the risks, after a review of postmarketing data showed that the reformulation may have encouraged users to shift from snorting Opana to injecting it by mixing it with large volumes of solvent.

The painkiller was even linked to a 2015 HIV outbreak in Indiana after people addicted to opioids shared needles while injecting Opana.

Endo pulled its product from the market in July.

The institute concluded in its report that while abuse-deterrent opioid formulations are a part of a larger strategy to fight the opioid epidemic, much more work needs to be done to better assess the drugs’ claims and justify their pricetags.

“The advent of new ADF opioids with potentially superior abuse-deterrent properties, as well as the lack of robust evidence on opioid diversion and switching to other opioids
or heroin, call for further research that will generate real-world evidence to understand the true health and economic impact of ADF opioids on the opioid abuse epidemic,” the report said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Pain Management, Pharmaceuticals Tagged With: Endo Pharmaceuticals

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS